Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 5
2016 2
2017 2
2018 3
2019 5
2020 2
2021 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets.
Nakagawa S, Miki Y, Miyashita M, Hata S, Takahashi Y, Rai Y, Sagara Y, Ohi Y, Hirakawa H, Tamaki K, Ishida T, Watanabe M, Suzuki T, Ohuchi N, Sasano H. Nakagawa S, et al. Breast Cancer Res Treat. 2016 Jan;155(1):65-75. doi: 10.1007/s10549-015-3668-9. Epub 2015 Dec 29. Breast Cancer Res Treat. 2016. PMID: 26715212
The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S, Omori K, Nakayama M, Mandai H, Yamamoto S, Kobayashi H, Sako H, Sakaida K, Yoshimura H, Ishii S, Ibaragi S, Hirai K, Yamashiro K, Yamamoto T, Suga S, Takashiba S. Nakagawa S, et al. Int Immunopharmacol. 2020 Jun;83:106429. doi: 10.1016/j.intimp.2020.106429. Epub 2020 Mar 26. Int Immunopharmacol. 2020. PMID: 32222639 Free article.
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, Kojima Y, Tsugawa K, Ohi Y, Sagara Y, Sato M, Ebata A, Harada-Shoji N, Suzuki T, Nakanishi M, Ohta T, Ishida T. Nakagawa S, et al. Breast Cancer Res Treat. 2024 Apr;204(3):453-463. doi: 10.1007/s10549-023-07209-2. Epub 2024 Jan 5. Breast Cancer Res Treat. 2024. PMID: 38180699 Free PMC article.
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S, Murakami T, Oka K, Asakura M, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Nagata D. Ohara K, et al. Among authors: nakagawa s. Diabetol Metab Syndr. 2020 May 1;12:37. doi: 10.1186/s13098-020-00545-z. eCollection 2020. Diabetol Metab Syndr. 2020. PMID: 32377235 Free PMC article.
Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor.
Minemura H, Takagi K, Miki Y, Shibahara Y, Nakagawa S, Ebata A, Watanabe M, Ishida T, Sasano H, Suzuki T. Minemura H, et al. Among authors: nakagawa s. Cancer Sci. 2015 Nov;106(11):1642-50. doi: 10.1111/cas.12808. Epub 2015 Oct 7. Cancer Sci. 2015. PMID: 26331797 Free PMC article.
Hemolytic Uremic Syndrome: An Increasingly Recognized Public Health Problem.
Murakami T, Akimoto T, Yamazaki T, Yoshizawa H, Okada M, Miki A, Nakagawa S, Ohara K, Sugase T, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D. Murakami T, et al. Among authors: nakagawa s. Clin Med Insights Case Rep. 2018 Jul 3;11:1179547618785137. doi: 10.1177/1179547618785137. eCollection 2018. Clin Med Insights Case Rep. 2018. PMID: 30083060 Free PMC article.
Fungal metabolite (+)-terrein suppresses IL-6/sIL-6R-induced CSF1 secretion by inhibiting JAK1 phosphorylation in human gingival fibroblasts.
Yamamoto S, Omori K, Mandai H, Nakayama M, Nakagawa S, Kobayashi H, Kunimine T, Yoshimura H, Sakaida K, Sako H, Ibaragi S, Yamamoto T, Maeda H, Suga S, Takashiba S. Yamamoto S, et al. Among authors: nakagawa s. Heliyon. 2018 Nov 26;4(11):e00979. doi: 10.1016/j.heliyon.2018.e00979. eCollection 2018 Nov. Heliyon. 2018. PMID: 30519664 Free PMC article.
The Fungal Metabolite (+)-Terrein Abrogates Ovariectomy-Induced Bone Loss and Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastogenesis by Suppressing Protein Kinase-C α/βII Phosphorylation.
Sakaida K, Omori K, Nakayama M, Mandai H, Nakagawa S, Sako H, Kamei C, Yamamoto S, Kobayashi H, Ishii S, Ono M, Ibaragi S, Yamashiro K, Yamamoto T, Suga S, Takashiba S. Sakaida K, et al. Among authors: nakagawa s. Front Pharmacol. 2021 Jun 8;12:674366. doi: 10.3389/fphar.2021.674366. eCollection 2021. Front Pharmacol. 2021. PMID: 34168561 Free PMC article.
22 results